EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer: Clinical Utility and Limitations

Zuzanna Zofia Ratka, Marta Woźniak

International Journal of Molecular Sciences · 20.11.2026 · 27 (22) · 10453

DOI: 10.3390/ijms272210453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.11.2026. Verfasst von Zuzanna Zofia Ratka und 1 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) is an important biomarker in ovarian cancer, but available assays interrogate different biological features and are not fully interchangeable. This structured narrative review examines HRD biology, testing strategies, clinical utility, and limitations using PubMed and Scopus, with emphasis on the past decade and older seminal studies. The clinical synthesis focuses predominantly on advanced high-grade epithelial ovarian cancer, particularly high-grade serous ovarian carcinoma, and first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance. Homologous recombination repair (HRR) gene alterations, genomic scars, and functional RAD51 assays represent distinct layers of repair biology. Genomic-scar assays have treatment-specific clinical validation, whereas RAD51 testing offers a functional readout whose clinical utility remains under investigation. Assay thresholds, specimen quality, tumor heterogeneity, and treatment history influence classification; an inconclusive result must be distinguished from a negative result. Progression-free survival benefit should also be separated from overall-survival benefit and from prognostic association. Emerging circulating, computational, epigenetic, and metabolomic biomarkers may provide complementary information but lack sufficient validation to replace established testing. Prospective studies should establish whether integrated genomic and functional assessment improves treatment decisions and patient outcomes beyond current approaches.

Zitieren

APA

Ratka, Z. Z., & Woźniak, M. (2026). Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer: Clinical Utility and Limitations. International Journal of Molecular Sciences, 27(22), 10453. https://doi.org/10.3390/ijms272210453

Vancouver

Ratka ZZ, Woźniak M. Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer: Clinical Utility and Limitations. International Journal of Molecular Sciences. 2026;27(22):10453. doi:10.3390/ijms272210453

BibTeX
@article{Ratka2026,
  author = {Ratka, Zuzanna Zofia and Woźniak, Marta},
  title = {Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer: Clinical Utility and Limitations},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10453},
  doi = {10.3390/ijms272210453}
}
Kostenlos starten →